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Abstract
Background: There is a major need for longitudinal research examining the experiences of people with dementia
and their primary carers, as relatively little is known about how the factors associated with capability to ‘live well’
vary over time. The main aim of the IDEAL-2 study is to investigate how and why, over time, people with dementia
and their primary carers might vary in their capability to live well with dementia, whilst exploring both their use of
health and care services and their unmet needs.
Methods: IDEAL-2 will build on the Improving the experience of Dementia and Enhancing Active Life (IDEAL)
cohort of 1547 people (who, at recruitment between July 2014 and July 2016, had mild-to-moderate dementia),
and their 1283 primary carers in Great Britain. The existing cohort will be enriched with additional participants with
mild-to-moderate dementia (and their primary carers where available and willing) from the following groups:
people with rarer forms of dementia, and/or those who are ≥90 years or < 65 years of age at time of recruitment.
We will assess the primary outcome, capability to live well with dementia, and the factors influencing it using
questionnaires at yearly intervals for 3 years. Additionally, we will seek to link the cohort data with administrative
data to obtain information about health service use. Some participants will be invited for in-depth face-to-face
interviews. The cohort study will be supplemented by linked research focusing on: the co-production of new
measures of living well; including the perspectives of people with advanced dementia living in residential care
settings; including people with dementia from black, Asian, and minority ethnic groups; and understanding the
experience of people living with undiagnosed dementia.
Discussion: IDEAL-2 will provide evidence about the key indicators of, and factors associated with, living well over
the course of dementia and how these differ for particular subgroups. It will tell us which combinations of services
and support are most beneficial and cost-effective. Moreover, the IDEAL-2 study will gather evidence from under-
researched groups of people with dementia, who are likely to have their own distinct perceptions of living well.
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Background
Relatively few intervention trials have demonstrated ben-
efits in terms of improving quality of life and well-being
for people with dementia [1, 2], and we still know rela-
tively little about how to improve the experience of
people with dementia and their primary carers (e.g. rela-
tives/friends) in real-world contexts. If interventions and
initiatives that genuinely enhance this experience are to
be developed, we first need a full understanding of the
wide range of factors that influence whether people with
all types of dementia can ‘live well’ with the condition,
including people from black, Asian and minority ethnic
(BAME) groups, and people with advanced dementia.
Researchers and members of the general public have
different understandings of what the concept of living
well actually means. In the literature, the concept of liv-
ing well with dementia is usually operationalised in
terms of good quality of life or health-related quality of
life [3]. In our previous work [4] we have developed a
conceptual framework for understanding living well that
emphasises that the capability to live well with dementia
is broader than quality of life [5] and includes well-being
[6] and satisfaction with life [7]. We have also postulated
that the capability to live well with dementia is shaped
by several key factors: capitals, assets, and resources;
challenges; access to and use of services; and the degree
of adaptation achieved by the person and family [4]. This
framework will continue to shape the development of
our theoretical work throughout the IDEAL-2 study: Im-
proving the experience of Dementia and Enhancing ac-
tive Life: a longitudinal perspective on living well with
dementia.
Importantly, people with dementia also have their own
understanding of living well with dementia, but standard
questionnaires do not always fully capture the most rele-
vant aspects for each individual. One reason for this is
that involvement of people with dementia in the devel-
opment of living well measures has not yet extended to
genuine co-production [8] where people with dementia
work on equal terms with researchers to develop a scale
that reflects their experiences and needs, something that
researchers increasingly acknowledge as important [9,
10]. The construction of a new measure of the broader
construct of living well in the IDEAL-2 study presents
an important opportunity for people living with demen-
tia to work together with the project team to co-produce
a measure.
The IDEAL-2 study will also gather evidence from
under-researched groups of people with dementia, who
are likely to have their own distinct perceptions of living
well [11]: people with advanced dementia living in resi-
dential care settings, people from BAME communities,
and people who meet criteria for a diagnosis of dementia
but have not accessed specialist services. More specifically,
individuals with advanced dementia represent a group that
is largely neglected in research. Little is known about their
quality of life and evidence-based psychosocial interven-
tions designed to meet their needs are almost entirely
lacking [12–14]. Yet many people with advanced dementia
are able to say what is important to them [11, 15], while
others can communicate their feelings and preferences
non-verbally [16, 17]. More effort is needed to obtain their
views and include them in research, and in the IDEAL-2
study we aim to develop a communication toolkit to
achieve this.
Next, evidence indicates that there is increased preva-
lence of dementia in people of African-Caribbean and
South Asian ethnicity living in the United Kingdom
(UK) [18, 19]. We know that these groups are less likely
to access health services [20], leading to low diagnosis
rates, and that they are at risk of lower well-being, for
example due to high levels of loneliness [21]. In the
IDEAL-2 study, we aim to identify how we can best
understand the needs of people with dementia from
BAME communities and ensure that their voices are
represented in research and policy making. We will in-
vestigate ways to ensure that services provided by the
National Health Service (NHS) are accessible and provide
appropriate support to BAME communities. Levels of
family care provision are also significantly higher in the
African-Caribbean and South Asian groups in Britain than
for other groups. There has been little research about the
role of male primary carers in African-Caribbean and
South Asian ethnicity communities despite the fact that
approximately 40% of primary carers are male and pre-
dominantly spouses [22], and this will be a focus for fur-
ther exploration in the study.
Lastly, people who meet the criteria for a diagnosis of
dementia but have no formal diagnosis and have not
accessed specialist services are largely unrepresented in
research. We know that at least one third of those living
with dementia in the UK have no formal diagnosis [23].
In the IDEAL-2 study, we aim to understand more about
the experiences of people living with undiagnosed de-
mentia and their primary carers and to identify factors
that predict the likelihood of not receiving a diagnosis.
In summary, using both quantitative and qualitative
methods, we aim to assess the key indicators of, and fac-
tors associated with, living well over the course of de-
mentia and how these differ for particular subgroups.
This wealth of evidence will also tell us which combina-
tions of services and support are most beneficial and
cost-effective, and it will offer a means to identify people
at risk of decline in living well who would benefit from
targeted support. The central element of IDEAL-2 will
be three further yearly follow-ups of the IDEAL cohort
[4]. At the time of the first follow-up we will enrich the
cohort with additional participants from groups that
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were underrepresented in IDEAL or where small num-
bers were included; data from these participants will be
added to the data from IDEAL waves 1–3 to allow for
more extensive sub-group analyses. Continuation of the
cohort will be supplemented by five linked studies;
IDEAL-2 consists of six studies in total, which are de-
scribed below.
Research questions/objectives
We will address the following broad research questions
aimed at creating innovations in understanding, methods,
policy and practice:
1. How do key indicators of living well change as
dementia progresses and what are the factors
influencing these trajectories of capability to live
well with dementia?
2. How do patterns of service use and costs relate to
living well, and which combinations of services and
support from families are both beneficial and cost-
effective?
3. How can we ensure that evaluation of key
indicators of living well accurately and
comprehensively reflects the individual and
collective experience of people living with
dementia?
4. What are the best ways to include the perspectives
of people with advanced dementia?
5. What can we learn about the perspectives of people
with dementia from BAME groups?
6. What can we learn about the perspectives of people
living with undiagnosed dementia?
Methods/design
The IDEAL-2 study will build on the IDEAL cohort [4]
of 1547 people with mild-to-moderate dementia and
1283 primary carers. Briefly, IDEAL is a mixed-methods
longitudinal study that aimed to identify what helps, or
makes it difficult, to live well in the context of having
dementia or caring for a person with dementia. The
IDEAL cohort was recruited between July 2014 and July
2016 and assessed at three time points: T1 (baseline), T2
(12 month follow up) and T3 (24 month follow up). The
central element of IDEAL-2 is three further yearly
follow-ups (T4, T5 and T6) of the IDEAL cohort with
T4 being 24 months after T3. At the time of the first
IDEAL-2 follow-up (T4) we will enrich the cohort with
additional participants with specific characteristics; their
information will augment the data from IDEAL T1 and
subsequent assessments to increase numbers in small
sub-groups. The cohort study will be supplemented by
linked studies focusing specifically on co-production of
new measures of living well; on people living in residential
care with advanced dementia; on people with dementia
from BAME groups; and on people living with undiag-
nosed dementia. The IDEAL-2 programme consists of six
studies in total (Fig. 1). The funding for the study started
on 1st January 2018 and the study end date is 31 Decem-
ber 2022. The recruitment started on 25th August 2018.
Study one: IDEAL-2 cohort: Study design
Primary research questions/objectives
1. How do key indicators of living well change as
dementia progresses and what are the factors
influencing these trajectories of capability to live
well with dementia?
Secondary research questions/objectives
1. How do key indicators of living well differ for
particular subgroups (e.g. different diagnostic
groups, age-groups, gender, etc.)?
2. How is the situation of the person with dementia
associated with the primary carer living well and
vice versa?
3. How can we accurately identify people who are at
particular risk of decline in living well?
Study One is a mixed-method longitudinal study. The
design and flow of participants in Study One are shown
in Fig. 2. We will follow the IDEAL participants [4] at
three further time-points, 12 months apart (T4, T5, and
T6). In addition, we will enrich the IDEAL cohort by
recruiting additional participants with mild-to-moderate
dementia (a Mini-Mental State Examination (MMSE)
[24] score ≥ 15) and their primary carers (where available
and willing) in groups underrepresented (less than 10%)
in the IDEAL cohort (people diagnosed with rarer types
of dementia (frontotemporal dementia, dementia with
Lewy bodies, Parkinson’s disease dementia), or ≥ 90 years
old at the time of recruitment to the IDEAL-2 study).
We will also recruit more participants aged under 65
(9% of the IDEAL cohort) at the request of our Patient
and Public Involvement (PPI) group (Action on Living
Well: Asking You - ALWAYs).
Quantitative assessments of the IDEAL-2 cohort par-
ticipants using questionnaires and brief tests of cognitive
ability will be conducted at T4, T5, and T6; participants
and their primary carers will be assessed in their homes
or usual place of residence.
A small number (N = 25–30) of participants experien-
cing key events (e.g. recent retirement or bereavement)
and care transitions (e.g. moving to a care home or nurs-
ing facility) will be invited, at different time points through
the IDEAL-2 cohort study, to take part in in-depth inter-
views. Firstly, through clinical teams, we will identify
people moving into residential care to interview. We will
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also interview a relative and a member of care staff, and
observe the person’s daily life to capture embodied aspects
of living well. In addition, based on the data collected as
part of the questionnaires, we will identify and interview
those living with dementia who are still in employment, or
who have recently retired to explore how work, and retir-
ing from work, affects people’s experience of living with
dementia. Finally, some participating primary carers will
experience the death of the person with dementia during
the study. We will identify these bereaved carers through-
out the time of the study to explore their perceptions of
end of life care and their subsequent experiences.
Study one: IDEAL-2 cohort: Participant eligibility
Individuals were potentially eligible to participate in the
IDEAL study [4] if they had a clinical diagnosis of de-
mentia (any sub-type) and MMSE [24] score of 15 or
above and lived in their own homes at the time of re-
cruitment, with no restriction on age. IDEAL study par-
ticipants will be invited to take part in the IDEAL-2
study if a) they did not exit the IDEAL study due to
withdrawal or loss to follow up; and b) have previously
agreed to being contacted should resources become
available to find out how well they are doing after a lon-
ger period. People who lack capacity to consent will still
be eligible to take part. Participants will be excluded if
there is any known potential for home visits to pose a
significant risk to NHS research network staff or mem-
bers of IDEAL-2 study team.
New participants enriching the IDEAL cohort will be
invited to take part in the IDEAL-2 study if they a) have
a clinical diagnosis of dementia; b) have an MMSE
score ≥ 15; c) have a good understanding of the English
language to allow completion of the assessment mea-
sures; d) fit one of the criteria for additional recruitment
as described earlier; and e) live in the community on
entry to the study. Participants will be excluded if they
a) have co-morbid terminal illness at T4; b) are unable
to provide informed consent at T4; and c) represent any
known potential for home visits to pose a significant risk
to researchers collecting data (the same exclusion cri-
teria as for IDEAL study entry).
Overall, participating in the IDEAL-2 cohort will not
preclude participation in intervention trials or other ob-
servational studies; such participation will be noted.
In IDEAL, together with each participant with demen-
tia, we sought to recruit a primary carer where there is
one available. The same procedure will be followed for
new recruitment in IDEAL-2. For the purposes of the
study, we consider a primary carer to be someone who
looks after the person with dementia on a regular basis,
at least 3 days a week, and knows the person with
Fig. 1 Structure of the IDEAL-2 study
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dementia well enough to provide meaningful answers
about his/her capability to live well. If primary carers
took part in the IDEAL study, they will be invited to
take part in the IDEAL-2 study even if the person with
dementia whom they support does not take part in
IDEAL-2. In the case of newly-recruited participants
joining the IDEAL cohort, the primary carer will only be
invited to take part in the study if the person with de-
mentia consents to take part.
In cases where participants have moved into a care
home, we will also recruit a member of care staff who is
involved in the participant’s care and is able to provide
information on the participant’s well-being.
Study one: IDEAL-2 cohort: Setting
As the IDEAL study [4] participants were recruited from
29 NHS sites in England, Scotland and Wales, our
Fig. 2 Flow of participants in the IDEAL-2 cohort
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IDEAL-2 cohort participants will be located similarly in
the community across England, Scotland and Wales.
Those IDEAL participants who moved into residential
care between IDEAL and IDEAL-2 will continue to be
included along with a primary carer (friend/family) and
a member of care staff, if available. The same will apply
for all IDEAL-2 cohort participants who move into resi-
dential care at T5 or T6.
Study one: IDEAL-2 cohort: Recruitment
New IDEAL-2 cohort participants will be recruited from
memory services, old age mental health services, move-
ment disorder services, specialist memory clinics that
have a particular focus on fronto-temporal dementia,
working age dementia services for people with young
onset dementia and other specialist clinics within par-
ticipating NHS sites in England, Scotland and Wales. Re-
cruiters will draw on contacts with community mental
health teams, general practitioner (GP) practices, social
services and voluntary sector groups as appropriate. In
addition to the original IDEAL NHS sites we will recruit
from new NHS sites to support recruitment where ne-
cessary. NHS sites may also potentially recruit through
the online Join Dementia Research register [25]. It is
possible that some of the new participants will be re-
cruited through our project partners (e.g. Alzheimer’s
Society) and other agencies through promotion of the
IDEAL-2 study in relevant magazines, newsletters, and
through media and social media channels.
Potential participants (either from the IDEAL cohort
or newly-identified) will be contacted by telephone or in
person (e.g. during clinic appointments, in care homes)
or by invitations approved by the Research Ethics Com-
mittee (REC) to establish whether they are interested in
participating in the IDEAL-2 study. After 14 days,
non-responses to the initial contact through letter or
phone will be followed up by NHS research network
staff once, to cover the possibility that letters and mes-
sages could be mislaid due to memory difficulties. Those
participants approached with an invitation letter or face
to face will receive, at the same time, a short information
sheet. Those approached by telephone will be sent the
same short information sheet following the call. Those
participants who express interest in taking part in
IDEAL-2 will be followed up by a telephone call to talk
through the information sheet, and ask any questions
they may have. Once participants have agreed in
principle to taking part in the IDEAL-2 study, the re-
search network staff member and participant will agree
a date and a venue for the visit to take informed consent
(for Study One and data linkage), and the research net-
work staff member will send the participant the
full-length information sheet and data linkage informa-
tion sheet. Participants who move out of NHS site
catchments areas during the course of the study will be
followed up by an IDEAL-2 team member.
In the case of participants who reside in a care home,
a member of care staff who is involved in the partici-
pant’s care and is able to provide information on the
person’s well-being will also be invited to take part in
the IDEAL-2 study either face-to-face or via phone or
invitation letter. Members of care staff will be provided
with an information sheet to enable them to make an in-
formed decision about whether they would like to take
part in the IDEAL-2 study. If they agree, they will be
contacted to schedule a date and venue for taking in-
formed consent and completing the questionnaires.
At T5 and T6 participants will be re-contacted by tele-
phone or by REC-approved invitation letter or in person
(e.g. during clinic appointments, in care homes) and in-
vited to take part in the follow ups.
The steps described above will be conducted by NHS re-
search network staff or by an IDEAL-2 team member
based at the University of Exeter co-ordinating centre, all
of whom will be trained in informed consent procedures
as part of their Good Clinical Practice training and be fa-
miliar with General Data Protection Regulation.
Invitations to take part in the qualitative interviews to-
gether with information sheets will be sent to a purpos-
ive sample selected from participants who agreed to be
approached about a further interview. The exact number
of the interviewees will depend on access to the relevant
subgroups and on data saturation. We will focus initially
on three groups: those moving into residential care (per-
son with dementia, family member/friend and staff
member), those who are working or who have recently
retired (person with dementia and family member/
friend) and primary carers who are recently bereaved.
After a period of a week, the invitation letters will be
followed up by a telephone call to participants, to talk
through the information sheet and to give them the op-
portunity to ask any questions they may have. Once par-
ticipants have agreed in principle to take part in an
interview, the researcher and participant will agree a
date and a venue for the interview to take place. The
interview will be preceded by further discussion and ex-
planation of the study and the taking of written in-
formed consent.
Study one: IDEAL-2 cohort: Consent
It will be the responsibility of the NHS research network
staff member (or an IDEAL-2 team member) to obtain
written informed consent from each participant where
possible prior to participation in the study, following ad-
equate explanation of the study. Consent will be taken
from the person with dementia and from a family mem-
ber/friend, and for those in care homes, also from a
member of care staff if available. No study procedures
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will be conducted prior to the participant giving consent
by signing the appropriate consent form. If people with
dementia lack capacity on joining IDEAL-2 but gave ap-
propriate consent during IDEAL, no study procedures
will be conducted prior to discussions with the partici-
pant’s consultee (in England and Wales) or nearest rela-
tive, guardian or welfare attorney (in Scotland).
All potential participants providing consent for entry
to the IDEAL-2 cohort study will be asked about their
willingness to be approached for an in-depth interview.
Those participants who agree to be approached for
qualitative interviews will be screened using the data
they have already provided as part of the IDEAL-2 study,
and those identified through purposive sampling as eli-
gible for participation in qualitative in-depth interviews
will be provided with a separate information sheet and
consent form that relates specifically to their involve-
ment in this part of the study.
This study will involve participants who may lack cap-
acity to consent to take part in the study. NHS research
network staff members (or IDEAL-2 team members) will
assess whether participants have capacity to give consent
to participation at T4, and to continued participation at
T5 and T6. They will already have experience of inter-
acting with and assessing people with dementia, and
they will receive specific training from the research
team. They will use a checklist to ensure that they make
a thorough evaluation. As the IDEAL-2 cohort includes
participants from England, Wales and Scotland we will
follow the guidelines stipulated in the Mental Capacity
Act (2005) [26] and the Adults with Incapacity
(Scotland) Act 2000 [27] in relation to including partici-
pants lacking capacity in research. If the participant is
judged to be unable to give informed consent at T4, dif-
ferent procedures will apply for IDEAL participants and
new participants enriching the IDEAL cohort. Some
returning IDEAL participants may now lack capacity to
consent and in IDEAL we addressed this prospectively
to facilitate continued inclusion in the future – partici-
pants at the time of joining the IDEAL study gave con-
sent to be contacted should resources become available
to find out how well they are doing after a longer period
and they were asked to nominate a personal consultee
(when participants lived in England or Wales) or legal
representative such as guardian or welfare attorney or
nearest relative (when participants lived in Scotland) in
case they lost the capacity to consent. If a personal con-
sultee was not available we would consult a nominated
consultee (England and Wales). Therefore, if an IDEAL
participant in England and Wales lacks capacity to give
informed consent to join the IDEAL-2 study, we will
seek the opinion of the participant’s personal consultee
on the views and feelings of the participant. If an IDEAL
participant in Scotland lacks capacity to give informed
consent to join the IDEAL-2 study, we will ask the par-
ticipant’s guardian or welfare attorney authorised to take
decisions about the research or the participant’s nearest
relative to give their consent. New participants with
mild-to-moderate dementia recruited to the IDEAL-2
cohort must have capacity to give informed consent at
the time of joining the IDEAL-2 study (T4) but again it
is possible that they may lose capacity to consent
through the study (at T5 and/or T6). On entry to the
IDEAL-2 cohort, the issue of continuing participation
will be discussed, and each participant will be asked to
nominate a personal consultee (or guardian or welfare
attorney or nearest relative) who can advise on the ap-
propriateness of continued participation in the event of
loss of capacity.
Ethical approval was received from the Wales Research
Ethics Committee 5 – Bangor (18/WA/0111) on 20
March 2018 to conduct Study One in England and
Wales and the approval from Health Research Authority
was granted on 26th March 2018. Ethical approval was
received from Scotland A REC (18/SS/0037) on 30th
May 2018 to conduct Study One in Scotland. The study
has been adopted by the National Institute of Health Re-
search Portfolio registration number: 37955.
Study one: IDEAL-2 cohort: Assessments
For participants who took part in IDEAL, the T4, T5
and T6 assessments will be conducted during one home
visit at each time point. New participants joining the
IDEAL cohort at T4 will receive an additional visit at T4
to gather baseline information comparable to that ob-
tained at IDEAL T1. Visits to people with dementia and
their primary carers are expected to last up to 2 h each.
The participants will be offered a small shopping vou-
cher (£10) as a token of appreciation for taking part in
the study upon completion of the assessment at each T4,
T5 and T6 assessments.
IDEAL-2 cohort participants, and their primary carers
where they are contributing, will be assessed using ques-
tionnaires at each time-point by a member of NHS re-
search network, or in a few cases by a member of the
IDEAL-2 team based at the coordinating centre. NHS
research network staff will receive yearly training from
the study team before each assessment (at T4, T5 and
T6, respectively). In the case of people with dementia,
all questions will be read aloud by researchers collecting
data. Primary carers will complete the questionnaires
themselves.
The IDEAL-2 cohort assessment is based on our holis-
tic framework [4]. We also took into account feedback
from IDEAL study participants as well as researchers
collecting data in IDEAL. The format is sufficiently flex-
ible to allow length and level of detail to be tailored to
the needs of the individual during the assessment, for
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example by highlighting key questions and by using
show cards [28, 29]. Details of the measures that we plan
to collect in the IDEAL-2 study at T4 are provided in
Additional file 1.
Study one: IDEAL-2 cohort: Withdrawal
As part of the information sheets, we will inform partici-
pants that they can withdraw at any time during the
study, without having to give a reason. If a participant
who lacks mental capacity to consent gives any indica-
tion of not wanting to continue to take part, we will
withdraw the participant from the study. The participant
will also be withdrawn if the personal/nominated con-
sultee (or guardian or welfare attorney or nearest rela-
tive) advises against continued participation.
If participants withdraw, we will use the information
participants provide up to that point in line with the
General Data Protection Regulation, unless they indicate
that they do not want us to.
Study one: IDEAL-2 cohort: Adverse events
This is a low-risk observational study and, accordingly,
no formal adverse event monitoring is planned. How-
ever, events may come to the attention of the research
team which will be recorded using an adverse event
reporting form. Research staff working on the IDEAL-2
study will notify the local Principal Investigator or Chief
Investigator when such events occur.
Study one: IDEAL-2 cohort: Sample size calculation
For the IDEAL-2 cohort, the participants will be
re-consented from the ongoing IDEAL study. Between
2014 and 2016 IDEAL recruited 1547 people with de-
mentia; 83% had a primary carer participating giving a
total of 1283 primary carers. For the present study, the
sample size will be determined by the number of IDEAL
participants who agree to take part in the IDEAL-2
study. In addition we will recruit new participants, and
their primary carers where available and willing, to en-
rich the IDEAL cohort in specific sub-groups that con-
stituted fewer than 10% of the cohort at T1. These will
be people diagnosed with rarer types of dementia (fron-
totemporal dementia, dementia with Lewy bodies, Par-
kinson’s disease dementia), and/or aged either < 60 or ≥
90 years at the time of recruitment. Combining data
from these new participants with data collected from
IDEAL participants at T1 will improve our capability to
conduct meaningful sub-group analyses. Once we reach
the target for each enrichment group (increasing the
number in that particular sub-group to the equivalent of
10% of the IDEAL cohort at T1) we will stop the recruit-
ment of additional participants.
Study one: IDEAL-2 cohort: Analysis plan
The IDEAL-2 cohort will provide longitudinal data on
living well measures as well as social, psychological and
physical health factors in people with dementia and their
primary carers. Longitudinal analysis will investigate
changes in key variables over time, examine predictors
of capability to live well or decline in capability to live
well, and compare different patterns across subgroups.
As well as analysing data for people with dementia and
carers separately, we will focus on the dyadic relation-
ships between people with dementia and their primary
carers and examine how the situation of each partner in-
fluences the well-being of the other over time using the
actor-partner independence model, extended to also in-
corporate a third level of data where the carer acts as an
informant on behalf of the person with dementia.
The qualitative interview data collected as part of the
IDEAL-2 cohort and the open-ended questions collected
using questionnaires will be analysed using a thematic
approach [30].
Study two: Determinants of service use patterns and
costs: Study design
Primary research questions/objectives
1. How do patterns of service use and costs relate to
living well, and which combinations of services and
support from families are both beneficial and cost-
effective?
Secondary research questions/objectives
1. What are the services that people with dementia
use, what influences service use and what are the
associated costs?
2. How do services and unpaid care influence the
capability to live well with dementia?
This study involves analysis of IDEAL-2 cohort data
collected under Study One from a health economic per-
spective. Therefore, as part of the IDEAL-2 assessments
we will collect information on service use and the asso-
ciated costs. We will describe the information using
standard descriptive statistical methods, multilevel and
linear growth curve modelling. Service use and costs will
be summarised by key characteristics of sample mem-
bers with dementia (including age, gender, type of de-
mentia, severity of needs, comorbidities) and locality.
Trends over time (i.e. from one follow up to another)
will also be reported. To calculate costs (by service, sec-
tor or overall), the service use measures in IDEAL and
IDEAL-2 will be weighted by their unit costs and aggre-
gated. Unit costs will reflect long-run marginal oppor-
tunity costs and will be drawn from publicly available
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sources wherever possible, such as the annual Personal
Social Services Research Unit volume [31] and NHS Ref-
erence Costs [32]. Costs will also be attached to unpaid
care, estimated from information on volume and type of
support, the opportunity cost of lost work (wage rate)
for primary carers in paid employment, and replacement
cost for those not in paid employment based on (for ex-
ample) the cost of a home care worker. Medication costs
will be included, based on current prices to the NHS.
We will then explore how service use patterns and
their costs are associated with individuals’ needs and a
range of other personal characteristics and contextual
factors, adjusting for all other relevant factors. These
analyses, including estimation of cost functions [33], will
be based on multilevel, general linear and structural
equation modelling, paying attention to possible
non-normal distributions, non-linear associations and
endogeneity. Previous research in other fields demon-
strates the feasibility and usefulness of such approaches
[34–36]. For instance, in the analyses we will examine
whether the levels and composition of costs differ be-
tween groups with different characteristics (e.g. particu-
lar types of dementia or gender), whether the rate of
change of these costs varies between these groups and
whether that rate is linear or non-linear.
A parallel set of analyses will examine the influences of
services and unpaid care on quality of life and other out-
comes, again after adjusting for all other relevant factors.
These further multivariate analyses (‘production functions’
[37]) have not been explored previously in the dementia
field; they will be valuable in their own right, helping to
inform policy and practice discussions about service de-
ployment, cost and funding, but they can also be used in
what are effectively ‘naturalistic’ cost-effectiveness analyses
of different types and combinations of support for people
with dementia and their primary carers, conducted in
non-experimental, real-life conditions. These analyses will
again include general linear and structural equation mod-
elling, taking into account the possibility of non-normal
distributions, non-linear associations and endogeneity.
To examine cost-effectiveness, we will include indica-
tors of interventions in the multivariate analyses of costs
and outcomes, using estimated parameters from regres-
sion models to create incremental cost-effectiveness ra-
tios (and confidence intervals around them). Again, we
can build on previously developed methods by ourselves
and others [38–40]. By ‘interventions’ we mean the ser-
vices (individual or in combination) used in the natural-
istic context of a cohort design such as the IDEAL-2
study.
We plan to achieve comprehensive linkage to routine
health service datasets in the IDEAL-2 study, which will
allow us to compare responses from sample members and
administrative sources, as well as provide a contingency in
the event of missing data from the IDEAL-2 study ques-
tionnaires, providing a comprehensive picture of service
use.
Study two: Determinants of service use patterns and
costs: Consent
This study involves analysis of IDEAL-2 cohort data col-
lected under Study One from a health economic per-
spective. Consent will be therefore sought for this study
as part of Study One: IDEAL-2 cohort. In addition, our
analyses will be enhanced, subject to participant consent,
by data linkage to routine data. We will obtain separate
consent in written form from participants with dementia
to data linkage at T4. If an IDEAL participant in
England and Wales lacks capacity to give informed
consent to data linkage as part of IDEAL-2, we will seek
the opinion of the participant’s personal consultee on
the views and feelings of the participant. If an IDEAL
participant in Scotland lacks capacity to give informed
consent to data linkage, we will ask the participant’s
guardian or welfare attorney authorised to take decisions
about the research or the participant’s nearest relative to
give their consent.
Ethical approval was received from the Wales Research
Ethics Committee 5 – Bangor (18/WA/0111) on 20
March 2018 to conduct Study Two in England and
Wales and the approval from Health Research Authority
was granted on 26th March 2018. Ethical approval was
received from Scotland A REC (18/SS/0037) on 30th
May 2018 to conduct Study Two in Scotland.
Study three: Co-production of new measures of living
well: Study design
Primary research questions/objectives
1. How can we ensure that evaluation of key
indicators of living well accurately and
comprehensively reflects the individual and
collective experience of people living with
dementia?
Secondary research questions/objectives
1. How can we develop a standardised and personalised
measure of living well that reflect the experience of
people with dementia?
2. How can these living well measures be made
accessible for people with dementia?
As part of the IDEAL-2 study we will co-produce two
measures to aid the evaluation of the capability to live
well with dementia: a standardised questionnaire and an
individualised measure based on ‘personal questionnaire’
methodology. The standardised questionnaire will be a
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traditional type of measure where all participants are
given the same statements to rate on a Likert-type scale.
In the personal questionnaire approach, participants will
generate their own statements to rate on a similar
Likert-type scale; this is particularly useful for identifying
changes over time, and is used for example in psycho-
therapy research [41].
The co-production process will include four phases:
preparation; development; piloting; and testing. It will be
facilitated by our partner organisation Innovations in De-
mentia [42]. In Study Three, people with dementia will be
invited to act as co-researchers and will work in equal
partnership with the researchers from the IDEAL-2 team.
Additional people with dementia will be recruited as par-
ticipants for the piloting and testing phases.
In the preparation phase, as a first step, researchers
from the IDEAL-2 team will review the data that were
collected through in-depth face to face interviews as part
of the IDEAL study [4] and identify categories and
themes relevant to perceptions of quality of life,
well-being and satisfaction with life. As a next step, the
co-production team made up of people with dementia
and IDEAL-2 researchers will be invited to review this
information and suggest any additional topics not cov-
ered in the first step that they think are important. The
aim of the preparation phase is to produce a list of
topics and themes that are representative of the views
on living well by people with dementia. These will serve
as a starting point for the development of the
co-produced measures.
In the development phase, the co-production team will
review existing measures of quality of life, well-being and
satisfaction with life e.g. the use of language, response op-
tions, and mode of administration, and consider their
strengths and limitations. Based on the preferences of
co-researchers, the team will refine the themes from the
preparation phase and develop specific items and response
options for the co-produced questionnaire.
We aim to include 8–10 people with dementia to be
co-researchers. There are no inclusion or exclusion cri-
teria for co-researchers, other than that they have to be a
person living with dementia who would like to be involved
in the research. We will recruit these co-researchers from
the Dementia Engagement and Empowerment Project
(DEEP) groups (through Innovations in Dementia [42]) in
North West England. We hope to have a diverse mix of
people participating, including people from a range of eth-
nic backgrounds and at varying stages of dementia. The
nature of the co-researcher role will be made clear to
people before they are offered the opportunity, so that
they are able to decide if the role is right for them.
In the piloting phase, both the standardised measure
and the personalised measure of living well will be tested
with people with dementia (participants). Participants
will complete both measures with a member of the
co-production team. The co-production team will use
the feedback from the piloting phase to make final ad-
justments to both measures, and will also produce
guidelines for administration.
Lastly, in the testing phase, we will test both of the
co-produced measures with people with dementia (par-
ticipants) twice, with a two-week interval, to measure
test-retest reliability. Researchers from the IDEAL-2
team will then review the findings from this phase and
refine the measures if necessary. All members of the
co-production team will have access to the final prod-
ucts and have the opportunity to be engaged in dissem-
ination. Depending on the timeline, we hope to
introduce both of the co-produced measures in the T5
and/or T6 assessments of the IDEAL-2 cohort.
Study three: Co-production of new measures of living
well: Consent
Co-researchers will be given sufficient information about
their role and what will be expected of them during the
research, with information leaflets reviewed and ap-
proved by the University of Exeter REC. As they will act
as co-researchers (as opposed to participants) they will
not be asked to provide written consent, as implied con-
sent is more appropriate to co-production [43]. Innova-
tions in Dementia [42] who will facilitate Study Three
will work to their own ethical framework. During the
meetings, a set of clearly visible reminders will be dis-
played focusing on co-researchers’ rights, e.g. voluntary
participation; everything shared in the group space will
be anonymised; and that they are free to stop participat-
ing in the project at any time. Participants (people with
dementia) for the piloting and testing phase will be
asked to provide informed consent through information
sheets and the signing of consent forms, both of which
will be designed with co-researchers.
Ethical approval for Study Three was received from
the CLES – Psychology Ethics Committee (eCLESPsy0
00569 v4.0) on 22nd May 2018.
Study four: Perspectives of people living with advanced
dementia: Study design
Primary research questions/objectives
1. What are the best ways to include the perspectives
of people with advanced dementia?
Secondary research questions/objectives
1. What are the best methods that enable people with
advanced dementia to give their views about their
own capability to live well?
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2. What are the domains related to living well that
people with advanced dementia consider to be most
relevant and important?
3. How can we improve the lives of people with
advanced dementia?
In this study, we will develop and test a communication
toolkit which will be used to support the inclusion of the
perspectives of people with advanced dementia who still
use at least some verbal communication in research. We
aim to adopt a comprehensive approach to understanding
the ways in which people with advanced dementia com-
municate their thoughts, feelings and preferences, and
how we can use this knowledge to promote inclusion of
this particularly vulnerable group in research.
Currently, several methods exist that may facilitate
communication with people with advanced dementia
such as picture cards [11], talking mats [44–46], brief
observational methods such as AwareCare [47] and the
Positive Response Schedule [48], and a range of other
examples [49–54]. Namaste care also focuses on
non-verbal communication [55, 56]. To inform the de-
velopment of a communication toolkit to promote inclu-
sion in research we will conduct a systematic review of
these methods. We will interview dementia professionals
(e.g. speech and language therapists, occupational thera-
pists, psychologists), and other experts in non-verbal
communication to identify best practice in communicat-
ing with people living with advanced dementia. In
addition, we will conduct focus groups, observations and
workshop sessions.
We will use what we have learned to develop a com-
munication toolkit to train and support researchers in
gaining the perspective of people with advanced demen-
tia who still have some capability for verbal communica-
tion. We will then field-test and refine the toolkit in an
iterative process of engagement with people who have
advanced dementia living in care homes, and test its ro-
bustness with a further group of care home residents
with advanced dementia, who will be followed up after
12 months.
There will be a degree of purposive sampling, to make
sure that we have a mixture of people with advanced de-
mentia (different ages, different homes, different ethnici-
ties if possible, near-to-equal gender split, different
sub-types of dementia, and different stages of ‘advanced’
dementia). People will be potentially eligible to take part
in Study Four if they meet the following inclusion cri-
teria: a) they have a formal clinical diagnosis of any
sub-type of dementia; and b) they have moderate to se-
vere dementia as determined by any suitable assessment
method. Participants will be excluded if they are a)
acutely ill; b) thought to be imminently dying; or c) too
frail to engage with research staff.
Participants with advanced dementia will be recruited
primarily from a range of care homes with which the re-
search team has prior links. Potential participants will in
most cases be identified and recruited by care home staff
following discussion of inclusion and exclusion criteria
with a member of the research team. We will ask staff to
approach potentially eligible participants to explain the
study and provide them with a participant information
sheet in order to aid the invitation process. Once it is
ascertained that the person with dementia is happy to be
approached by the researcher, the researcher will then
talk to the potential participant. The researcher will
introduce him- or herself and re-explain the research in
a simplified and clear manner. If potential participants
are distressed or object to the introduction, they will be
thanked for their time and not included in the research.
Once the toolkit has been fully field-tested, we aim to
train researchers collecting data in the IDEAL-2 cohort
to use the toolkit to support their engagement with par-
ticipants with advanced dementia living at home or in
residential care at T5 and T6, and to explore how effect-
ive this is in enabling us to continue to include partici-
pants in the IDEAL-2 assessments whose dementia is
now at an advanced stage.
Study four: Perspectives of people living with advanced
dementia: Consent
It will be the responsibility of the NHS research network
staff member (or an IDEAL-2 team member) to obtain
written informed consent from each participant where
possible prior to participation in the study, following ad-
equate explanation of the study. We will be informed by
DEEP and Alzheimer’s Society guidelines alongside input
from the ALWAYs group about using clear, transparent
and user-friendly information sheets and consent forms.
We will also work with care home staff to understand
the most appropriate way to engage with the individual
during the information process. As participants with ad-
vanced dementia will all be living in England, the re-
search team will follow the guidelines of the Mental
Capacity Act (2005) [26] and presume the potential par-
ticipant has the mental capacity to consent prior to a
formal mental capacity assessment. Residents who have
capacity will provide formal, written consent. Study pro-
cedures will only be conducted where the participant
has given consent by signing the consent form or a per-
sonal or nominated consultee has deemed it appropriate
for the person who lacks capacity to participate. Where
it is established (using the criteria set out in the Mental
Capacity Act 2005 [26]), that a person lacks the capacity
to consent, then an approach will be made to someone
close to the resident who is able to act as a personal
consultee. If such a person is not identifiable, a nomi-
nated consultee (e.g. GP or health professional) will be
Silarova et al. BMC Public Health         (2018) 18:1214 Page 11 of 15
sought (in accordance with section 32 [3] of the Mental
Capacity Act 2005 [26]). Consultees will be asked for ad-
vice as to whether (a) the person should take part in the
project, and (b) what the person’s wishes and feelings
about taking part in the project would be likely to be if
the person had capacity to make the decision for him-
or herself (Mental Capacity Act 2005 [26], section 32
[4]). If the consultee’s advice is that participation in the
research can go ahead, the researcher will proceed but
will be sensitive to the responses of the person with de-
mentia. If by any means it is thought that the person
with dementia is signalling that he or she does not wish
to participate (or wishes to stop participating) – by
words, gestures, attitude, other vocalisations, emotional
displays, etc. – then the person will not be included in
the study (or his or her participation will cease). The re-
searcher will check continually that the person is still
consenting or assenting. Written prompts will be used
to facilitate this and to re-explain what is happening and
that the person is free to say whether he or she wishes
to stop.
Ethical approval was received from the Wales Research
Ethics Committee 5 – Bangor (18/WA/0111) on 20
March 2018 to conduct Study Four in England and
Wales and the approval from Health Research Authority
was granted on 26th March 2018.
Study five: Perspectives of people from BAME groups:
Study design
Primary research questions/objectives
1. What can we learn about the perspectives of people
with dementia from BAME groups?
Secondary research questions/objectives
1. Which factors support living well for people with
dementia and primary carers from BAME
communities?
2. How can we best support the inclusion of people
with dementia from BAME groups in future
research and health care service?
In this study, we will explore the potential for includ-
ing the perspectives of people with dementia from
BAME groups by focussing on people of African-Carib-
bean and South Asian ethnicity. In Phase One we will
work with community groups to build relationships and
trust, consulting community leaders and gatekeepers
and offering information and awareness sessions to de-
velop a strategy for identifying people with dementia. In
Phase Two we will conduct qualitative interviews with
people with dementia and their primary carers from
each community, to explore their experiences and
examine the feasibility of a wider survey. In Phase Three
we will work with people from these communities to de-
velop and implement a questionnaire based on the
IDEAL-2 cohort T4 quantitative assessment for
newly-recruited participants that is perceived as
culturally-acceptable by African-Caribbean and South
Asian communities. Once the questionnaire is devel-
oped, we will recruit and assess a larger group of people
with dementia from each community, with a primary
carer where available, and follow them up 12 months
later. In addition, we will develop a more in-depth ap-
proach to investigating the experiences and needs of
male primary carers of African-Caribbean and South
Asian ethnicity.
Study five: Perspectives of people from BAME groups:
Consent
Written consent will be sought from all participants tak-
ing part in different stages of this study (Phase 1–3).
Ethical approval for Study Five was received from
College of Health and Life Sciences Research Ethics
Committee, Brunel University London (10598-LR-Mar/
2018–12350-2) on 19th April 2018 for the community
leader interviews.
Study six: Perspectives of people living with undiagnosed
dementia: Study design
Primary research questions/objectives
1. What can we learn about the perspectives of people
living with undiagnosed dementia?
Secondary research questions/objectives
1. What is the evidence on the experiences of people
living with undiagnosed dementia and their primary
carers?
2. What is the evidence on how people living with
undiagnosed dementia differ from their diagnosed
counterparts?
3. What factors predict the likelihood of not receiving
a diagnosis of dementia?
To learn more about the experiences of people living
with undiagnosed dementia, we will use the Cognitive
Function and Ageing Study (CFAS)-Wales cohort [57] to
identify participants living with undiagnosed dementia
and examine their experience. Using the CFAS-Wales
data we aim to identify factors that predict the likelihood
of not receiving a dementia diagnosis. In addition, we
will recruit and interview participants taking part in the
CFAS-Wales study [57] whose data indicated that they
met criteria for dementia, determined by a diagnostic al-
gorithm and clinician review, but were undiagnosed as
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indicated by linkage of study data with GP registers. In
each case we will also interview a family member where
available. These interviews will provide insight into the
role that diagnosis plays (or does not play) in the every-
day lives of people living with or affected by dementia.
Study six: Perspectives of people living with undiagnosed
dementia: Consent
Written consent will be sought from all participants who
will take part in qualitative interviews.
Ethical approval for Study Six was received from the
Wales Research Ethics Committee 5 Bangor (10/
WNo01/37) on 3rd July 2018 as an amendment to the
CFAS-Wales study ethics application (reference number
10/WNo01/37; Chief Investigator: Professor Robert
Woods).
Discussion
Large longitudinal studies are rare in social science re-
search focusing on people with dementia, and little is
known about how capability to live well changes as de-
mentia progresses [16]. IDEAL-2 offers the opportunity
to address this evidence gap with data of exceptional
scope and duration. Together, the IDEAL and IDEAL-2
studies will constitute the largest study of living well
with dementia in Great Britain and possibly worldwide.
This will provide us with much-needed evidence about
the key indicators of, and factors associated with, living
well over the course of dementia and how these differ
for particular subgroups. It will tell us which combina-
tions of services and support are most beneficial and
cost-effective. At the individual level it will provide tools
with which to identify people at risk of decline in
well-being who would benefit from targeted support.
The evidence IDEAL-2 provides will benefit the lives
of people with dementia and their primary carers in the
future by shaping developments in policy, practice, re-
search and service provision. More broadly, it will con-
tribute to improving quality of life by enhancing care
practices, shaping community initiatives and widening
public understanding of how to support people with
dementia. It will provide a measure of living well
co-developed by people living with dementia. It will lead
to recommendations for a sustainable and accessible ap-
proach to monitoring ability to live well with dementia
and identifying unmet needs, with the potential to be
scaled up to population level. The availability of this rich
resource will also make it possible to contrast the ex-
perience of our cohort with that of their counterparts
without dementia through comparisons with data from
existing longitudinal studies. IDEAL-2 will contribute to
building capacity in dementia research and enhancing
workforce skills, with a strong focus on intervention de-
velopment that will catalyse longer-term improvements
in care and support, and will create a unique data set
that other researchers can use. Finally, ALWAYs group
members have told us that taking part in a study of this
kind can offer individual participants a valuable oppor-
tunity for reflection and can help in coming to terms
with the changes they are experiencing.
Additional file
Additional file 1: Content of the IDEAL-2 study questionnaires adminis-
tered to the cohort at T4 (DOCX 115 kb)
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